Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years of age~2. Undergoing a procedure which results in the need of a FTSG~3. Willing to provide written informed consent~Exclusion Criteria:~1. Age less than 18 years of age~2. Pregnant women~3. (Use of systemic drugs that can impede wound healing, such retinoids or immune-suppressive drugs)~4. Severe coagulation disorders~5. Severe, uncontrolled systemic comorbidities, such as diabetes, arthritis, etc.~6. Hypersensitivity to 0.25% timolol gel~7. Not willing to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 0.25% Timolol gel applied to full-thickness skin graft (Type: EXPERIMENTAL): 1. During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~2. During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~3. After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks
- Standard of Care dressings (Type: ACTIVE_COMPARATOR): 1. FTSG surgery as per SOC~2. After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).